Fast relief from migraine attacks using fast-disintegrating sublingual zolmitriptan tablets

References

• Lipton RB, Stewart WF. (1993). Migraine in the United States: A review of epidemiology and health care use. Neurology, 43:S6–10.
   PubMed Web of Science ®Google Scholar
• Hu XH, Markson LE, Lipton RB, Stewart WF, Berger ML. (1999). Burden of migraine in the United States: Disability and economic costs. Arch Intern Med, 159:813–818.
   PubMed Web of Science ®Google Scholar
• Fenuik W, Humphrey PPA, Perren MJ, Watts AD. (1985). A comparison of 5-hydroxytryptamine receptors mediating contraction in rabbit aorta and dog saphenous vein: Evidence for different receptor types obtained by use of selective agonists and antagonists. Br J Pharmacol, 86:697–704.
   PubMed Web of Science ®Google Scholar
• Pietrobon D, Striessnig J. (2003). Neurobiology of migraine. Nat Rev Neurosci, 4:386–398.
   PubMed Web of Science ®Google Scholar
• Pietrobon D. (2005). Migraine: New molecular mechanisms. Neuroscientist, 11:373–386.
   PubMed Web of Science ®Google Scholar
• Jhingran P, Cady RK, Rubino J, Miller D, Grice RB, Gutterman DL. (1996). Improvements in health-related quality of life with sumatriptan treatment for migraine. J Fam Pract, 42:36–42.
   PubMed Web of Science ®Google Scholar
• Cady RC, Ryan R, Jhingran P, O’Quinn S, Pait DG. (1998). Sumatriptan injection reduces productivity loss during a migraine attack: Results of a double-blind, placebo-controlled trial. Arch Intern Med, 158:1013–1018.
   PubMed Web of Science ®Google Scholar
• Lofland JH, Johnson NE, Batenhorst AS, Nash DB. (1999). Changes in resource use and outcomes for patients with migraine treated with sumatriptan: A managed care perspective. Arch Intern Med, 159:857–863.
   PubMed Web of Science ®Google Scholar
• Graham JR, Wolff HG. (1938). Mechanism of migraine headache and action of ergotamine tartrate. Arch Neurol Psychiatry, 39:737–763.
   Google Scholar
• Humphrey PP, Feniuk W, Perren MJ, Beresford IJ, Skingle M, Whalley ET. (1990). Serotonin and migraine. Ann N Y Acad Sci, 600:587–98; discussion 598.
   PubMed Web of Science ®Google Scholar
• Skyhøj Olsen T. (1990). Migraine with and without aura: The same disease due to cerebral vasospasm of different intensity. A hypothesis based on CBF studies during migraine. Headache, 30:269–272.
   PubMed Web of Science ®Google Scholar
• Humphrey PPA. (1991). 5-Hydroxytryptamine and the pathophysiology of migraine. J Neurol, 238:538– 544.
   Google Scholar
• Fenuik W, Humphrey PPA. (1989). Mechanisms of 5-hydroxytryptamine-induced vasoconstriction, Oxford:Oxford University Press.
   Google Scholar
• Zomig® and Zomig Rapimelt™ (2010) product information. AstraZeneca.
   Google Scholar
• Glen RC, Martin GR, Hill AP, Hyde RM, Woollard PM, Salmon JA et al. (1995). Computer-aided design and synthesis of 5-substituted tryptamines and their pharmacology at the 5-HT1D receptor: Discovery of compounds with potential anti-migraine properties. J Med Chem, 38:3566–3580.
   PubMed Web of Science ®Google Scholar
• Dowson AJ, Charlesworth B. (2002). Review of zolmitriptan and its clinical applications in migraine. Expert Opin Pharmacother, 3:993–1005.
   PubMedGoogle Scholar
• Volans GN. (1974). Absorption of effervescent aspirin during migraine. Br Med J, 4:265–268.
   PubMed Web of Science ®Google Scholar
• Seaber E, On N, Dixon RM, Gibbens M, Leavens WJ, Liptrot J et al. (1997). The absolute bioavailability and metabolic disposition of the novel antimigraine compound zolmitriptan (311C90). Br J Clin Pharmacol, 43:579–587.
   PubMed Web of Science ®Google Scholar
• Volans GN. (1974). Absorption of effervescent aspirin during migraine. Br Med J, 4:265–268.
   PubMed Web of Science ®Google Scholar
• Volans GN. (1975). The effect of metoclopramide on the absorption of effervescent aspirin in migraine. Br J Clin Pharmacol, 2:57–63.
   PubMed Web of Science ®Google Scholar
• Thomsen LL, Dixon R, Lassen LH, Gibbens M, Langemark M, Bendtsen L et al. (1996). 311C90 (Zolmitriptan), a novel centrally and peripheral acting oral 5-hydroxytryptamine-1D agonist: A comparison of its absorption during a migraine attack and in a migraine-free period. Cephalalgia, 16:270–275.
   PubMed Web of Science ®Google Scholar
• Tfelt-hansen P, Young WB, Silberstein SD. (2006). Antiemetics, prokinetics, neuroleptic and miscellaneous drugs in the acute treatment of migraine. Philadelphia: Lippincott Williams & Wilkins.
   Google Scholar
• Rapoport AM, Bigal ME, Tepper SJ & Sheftell FD. (2004) Zolmitriptan (ZOMIG®). Expert Rev Neurother, 4: 33–41.
   PubMedGoogle Scholar
• Alhalaweh A, Andersson S, Velaga SP. (2009). Preparation of zolmitriptan-chitosan microparticles by spray drying for nasal delivery. Eur J Pharm Sci, 38:206–214.
   PubMed Web of Science ®Google Scholar
• Aurora SK, Kori SH, Barrodale P, McDonald SA, Haseley D. (2006). Gastric stasis in migraine: More than just a paroxysmal abnormality during a migraine attack. Headache, 46:57–63.
   PubMed Web of Science ®Google Scholar
• Corveleyn S, Remon JP. (1998). Bioavailability of hydrochlorothiazide: Conventional versus freeze-dried tablets. Int J Pharm, 173:149–155.
   Web of Science ®Google Scholar
• Zydis® Fast Dissolve (2011) Catalent Pharma Solutions. Available at: http://www.catalent.com.
   Google Scholar
• Seager H. (1998). Drug-delivery products and the Zydis fast-dissolving dosage form. J Pharm Pharmacol, 50:375–382.
   PubMed Web of Science ®Google Scholar
• Ciper M, Bodmeier R. (2006). Modified conventional hard gelatin capsules as fast disintegrating dosage form in the oral cavity. Eur J Pharm Biopharm, 62:178–184.
   PubMed Web of Science ®Google Scholar
• Jeong SH, Park K. (2008). Development of sustained release fast-disintegrating tablets using various polymer-coated ion-exchange resin complexes. Int J Pharm, 353:195–204.
   PubMed Web of Science ®Google Scholar
• European pharmacopoeia (2002). Strasbourg, France, The directorate for the quality of medicines of the council of Europe 9EDQM.
   Google Scholar
• Schiermeier S, Schmidt PC. (2002). Fast dispersible ibuprofen tablets. Eur J Pharm Sci, 15:295–305.
   PubMed Web of Science ®Google Scholar
• Chandrasekhar R, Hassan Z, Alhusban F, Smith AM, Mohammed AR. (2009). The role of formulation excipients in the development of lyophilised fast-disintegrating tablets. Eur J Pharm Biopharm, 72:119–129.
   PubMed Web of Science ®Google Scholar
• Date PV, Samad A, Devarajan PV. (2010). Freeze thaw: A simple approach for prediction of optimal cryoprotectant for freeze drying. AAPS PharmSciTech, 11:304–313.
   PubMed Web of Science ®Google Scholar
• Price JC. (2000). Gelatin Monograph. London: Pharmaceutical Press.
   Google Scholar
• AlHusban F, Perrie Y, Mohammed AR. (2010). Formulation and characterisation of lyophilised rapid disintegrating tablets using amino acids as matrix forming agents. Eur J Pharm Biopharm, 75:254–262.
   PubMed Web of Science ®Google Scholar
• Shoukri RA, Ahmed IS, Shamma RN. (2009). In vitro and in vivo evaluation of nimesulide lyophilized orally disintegrating tablets. Eur J Pharm Biopharm, 73:162–171.
   PubMed Web of Science ®Google Scholar
• USP30-NF25 (2007) Pharmaceutical dosage forms: Ophthalmic preparations.
   Google Scholar
• Mizumoto T, Masuda Y, Yamamoto T, Yonemochi E, Terada K. (2005). Formulation design of a novel fast-disintegrating tablet. Int J Pharm, 306:83–90.
   PubMed Web of Science ®Google Scholar
• Sastry SV, Nyshadham JR, Fix JA. (2000). Recent technological advances in oral drug delivery - a review. Pharm Sci Technol Today, 3:138–145.
   PubMedGoogle Scholar
• Kuno Y, Kojima M, Ando S, Nakagami H. (2005). Evaluation of rapidly disintegrating tablets manufactured by phase transition of sugar alcohols. J Control Release, 105:16–22.
   PubMed Web of Science ®Google Scholar
• Djagny VB, Wang Z, Xu S. (2001). Gelatin: A valuable protein for food and pharmaceutical industries: Review. Crit Rev Food Sci Nutr, 41:481–492.
   PubMed Web of Science ®Google Scholar
• Cunningham FE, Baughman VL, Peters J, Laurito CE. (1994). Comparative pharmacokinetics of oral versus sublingual clonidine. J Clin Anesth, 6:430–433.
   PubMed Web of Science ®Google Scholar
• Kroboth PD, McAuley JW, Kroboth FJ, Bertz RJ, Smith RB. (1995). Triazolam pharmacokinetics after intravenous, oral, and sublingual administration. J Clin Psychopharmacol, 15:259–262.
   PubMed Web of Science ®Google Scholar
• Motwani JG, Lipworth BJ. (1991). Clinical pharmacokinetics of drug administered buccally and sublingually. Clin Pharmacokinet, 21:83–94.
   PubMed Web of Science ®Google Scholar
• Price TM, Blauer KL, Hansen M, Stanczyk F, Lobo R, Bates GW. (1997). Single-dose pharmacokinetics of sublingual versus oral administration of micronized 17 beta-estradiol. Obstet Gynecol, 89:340–345.
   PubMed Web of Science ®Google Scholar
• Wertz PW, Hoogstraate AJ & Squier CA. (1996). Biochemical basis of the permeability barrier in skin and oral mucosa. Hamilton, New York:Marcel Dekker, Inc.
   Google Scholar
• Odou P, Barthélémy C, Chatelier D, Luyckx M, Brunet C, Dine T et al. (1999). Pharmacokinetics of midazolam: Comparison of sublingual and intravenous routes in rabbit. Eur J Drug Metab Pharmacokinet, 24:1–7.
   PubMed Web of Science ®Google Scholar
• Rawas-Qalaji MM, Simons FE, Simons KJ. (2006). Sublingual epinephrine tablets versus intramuscular injection of epinephrine: Dose equivalence for potential treatment of anaphylaxis. J Allergy Clin Immunol, 117:398–403.
   PubMed Web of Science ®Google Scholar
• Wang Y, Zuo Z, Chen X, Tomlinson B, Chow MS. (2010). Improving sublingual delivery of weak base compounds using pH(max) concept: Application to propranolol. Eur J Pharm Sci, 39:272–278.
   PubMed Web of Science ®Google Scholar